TY - JOUR
T1 - Maternal vaccination against pertussis: a systematic review of the recent literature
AU - Gkentzi, Despoina
AU - Marangos, Marko
AU - Hsia, Yingfen
AU - Amirthalingam, Gayatri
AU - Heath, Paul T
AU - Ladhani, Shamez
AU - Katsakiori, Paraskeui
PY - 2017/5/3
Y1 - 2017/5/3
N2 - Objective This study is conducted to summarise and
present the current knowledge on antenatal vaccination
against pertussis with regard to national recommendations, coverage, immunogenicity, safety and effectiveness
of the current available vaccines.
Methods A systematic review of the literature in
English was undertaken from January 2011 to May 2016
with searches in four databases. The review conformed to
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines.
Results 47 studies fulfilled the inclusion criteria.
Antenatal vaccination against pertussis induces high
antibody concentrations in pregnant women, which are
efficiently transferred transplacentally to the fetus and
protect newborns when they are most vulnerable to
pertussis. This strategy has been demonstrated to be safe,
with no evidence of adverse pregnancy, birth or neonatal
outcomes. Several countries have already introduced
antenatal pertussis vaccination into their national
immunisation programme with varying vaccination
coverage influenced by various factors. Barriers to
achieving high immunisation rates could be improved
through better education of the public and healthcare
professionals.
Conclusions There is now an increasing body of
evidence to support the safety, immunogenicity and
effectiveness of antenatal vaccination to reduce the
morbidity and mortality associated with pertussis in
neonates and young infants before they receive their
primary immunisations. Narrowing the gap between
scientific evidence and public health policies is critical
in order to protect the most vulnerable as quickly as
possible. The lessons learnt have important implications
for implementation of new vaccines into the antenatal
immunisation programme.
AB - Objective This study is conducted to summarise and
present the current knowledge on antenatal vaccination
against pertussis with regard to national recommendations, coverage, immunogenicity, safety and effectiveness
of the current available vaccines.
Methods A systematic review of the literature in
English was undertaken from January 2011 to May 2016
with searches in four databases. The review conformed to
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines.
Results 47 studies fulfilled the inclusion criteria.
Antenatal vaccination against pertussis induces high
antibody concentrations in pregnant women, which are
efficiently transferred transplacentally to the fetus and
protect newborns when they are most vulnerable to
pertussis. This strategy has been demonstrated to be safe,
with no evidence of adverse pregnancy, birth or neonatal
outcomes. Several countries have already introduced
antenatal pertussis vaccination into their national
immunisation programme with varying vaccination
coverage influenced by various factors. Barriers to
achieving high immunisation rates could be improved
through better education of the public and healthcare
professionals.
Conclusions There is now an increasing body of
evidence to support the safety, immunogenicity and
effectiveness of antenatal vaccination to reduce the
morbidity and mortality associated with pertussis in
neonates and young infants before they receive their
primary immunisations. Narrowing the gap between
scientific evidence and public health policies is critical
in order to protect the most vulnerable as quickly as
possible. The lessons learnt have important implications
for implementation of new vaccines into the antenatal
immunisation programme.
U2 - 10.1136/archdischild-2016-312341
DO - 10.1136/archdischild-2016-312341
M3 - Article
VL - 102
SP - F456-F463
JO - Archives of Disease in Childhood - Fetal and Neonatal Edition
JF - Archives of Disease in Childhood - Fetal and Neonatal Edition
SN - 1359-2998
IS - 5
ER -